ArticleCardiovascular & hematological disorders drug targets2026
Exploring the Cardioprotective Potential of
Article in Cardiovascular & hematological disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe present study aimed to investigate the cardioprotective effect of Borago officinalis and its synergistic effect against isoproterenol-induced myocardial infarction in Sprague-Dawley (SD) rats. MATERIALS AND
methodsMyocardial infarction was experimentally induced in SD rats (Rattus norvegicus) using subcutaneous administration of isoproterenol (ISO) 85 mg/kg/s.c on days 20 and 21. Experimental animals were divided into five groups (5 animals each): normal control (NC), negative control (ISO), test drug Borago officinalis leaf extract (BOL) group, standard drug metoprolol (SDG) group, and combination of test drug Borago officinalis and standard drug metoprolol (BOM) group. Physical (heart grading and heart/body weight ratio), biochemical (CK-MB, LDH, AST, and ALT), troponin, oxidative stress (TBARS), and antioxidant parameters (SOD, CAT, GSH, and GPx) were assessed. Additionally, histopathological analysis of heart tissues was performed.
resultsISO significantly impaired cardiac function, as indicated by elevated biochemical markers (CK-MB, LDH, AST, and ALT) and oxidative stress markers (TBARS), and by heart tissue damage, with lowered antioxidant parameters (SOD, CAT, GSH, and GPx). Rats pre-treated with BOL, SDG, or their combination, BOM, effectively reduced these effects. Among them, the BOM group showed a significant cardioprotective effect, suggesting a synergistic action that outperformed metoprolol alone. DISCUSSION: Rats that were pre-treated with Borago officinalis extract showed significant improvement in biochemical, antioxidant, and histopathological markers compared to the rats in the ISO group. However, the combination of Borago officinalis and metoprolol provided the most pronounced protection, suggesting a synergistic effect.
conclusionThe findings of the present study highlight the potential of Borago officinalis as a complementary cardioprotective agent.
Indexed as
Identifiers
41220265What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.